Sunday, November 15, 2020

MSN Labs | 50 Openings | Walk-In Drive for Regulatory Affairs & DRA on 21st Nov' 2020


 

Walk- In Drive for Exe / Sr. Exe RA- Dept API- Division- R&D center

Regulatory Affairs API RA Dept. . In API Division,

Openings: 50
Job Description: (Regulatory Affairs - API Division)
Should have minimum of 2 to 8 years of experience in API Regulatory Affairs
Job Title: Executive / Senior Executive Experience: 2 to 8 years in API RA field

Education: B Pharma / M Pharma / M.Sc
Department: Regulatory Affairs - API
Job Title: Executive / Senior Executive

Experience: 2 to 8 years in API RA field Education: M Sc
Department: Regulatory Affairs -API
Job Profile:
1. Collecting and reviewing the documents received from various departments R&D, AR&D, QA, QC and Production etc at each and every stage of manufacturing of drug substances to minimize the errors at the time of submission to regulatory agencies.
2. Hands on experience on the preparation of DMFs and their registration processes in the major regulatory regions [US, Canada, Europe etc]..
3. Hands on experience on preparation of drug master files, Applicants Parts, Tech Pack, life cycle management [updates and amendments] and drafting of response to deficiencies and customer DMF review comments for all global regions.
4. Should have hands on experience on eCTD regulatory submission tools.
5. Should have knowledge on the requirements to respond to the deficiencies.
6. Participation in the cross functional team meetings and providing regulatory inputs to the Product Development Teams.
Drug Regulatory Affairs API RA Dept.

Experience: 2 to 7 Years
Position: Junior Executive / Executive /Senior Executive 

Date of Interview: 21.11.2020 (Saturday)

Interview Time: 9.00 AM to 1.00 PM

Venue Details:

MSN Laboratories Pvt. Ltd.,

R&D Center, Pashamylaram

Ph No : +91-8452304799

040-30438786

Work Location: MSN LS II (Chegunta , Chandampet)


Join for Regular Job Updates in What's App  & Telegram


Join What's App - Click Here

Join Telegram - Click Here

No comments:

Post a Comment